Physician profile
Hermes X Hernandez
NPI 1063778058
$6,817.88
in general payments reported to CMS, 2019-2025
28 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,362 · 2020: $492 · 2021: $1,165 · 2022: $949 · 2023: $1,075 · 2024: $1,051 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,136.28 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $976.46 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $858.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $579.68 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $542.06 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $476.80 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $425.76 | 2019-2024 | Lokelma, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.78 | 2020-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $258.33 | 2019-2024 | Eliquis, Camzyos |
| Otsuka America Pharmaceutical, INC. | $207.58 | 2019 | |
| Alexion Pharmaceuticals, INC. | $203.72 | 2019-2025 | Ultomiris |
| Gilead Sciences, INC. | $156.65 | 2021-2024 | |
| Boston Scientific Corporation | $112.55 | 2019-2024 | Watchman Flx |
| Sunovion Pharmaceuticals INC. | $112.10 | 2019 | |
| Paratek Pharmaceuticals, INC. | $80.59 | 2022-2023 | Nuzyra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $65.47 | 2025 | |
| Novo Nordisk INC | $53.61 | 2023-2024 | Rybelsus, Ozempic |
| Electromed, INC. | $44.23 | 2023 | Smartvest |
| Melinta Therapeutics, LLC | $39.16 | 2021-2022 | |
| Amgen INC. | $29.26 | 2019-2024 | Repatha |
| Shire North American Group INC | $27.52 | 2019 | |
| Abbott Laboratories | $24.94 | 2024 | Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.14 | 2025 | Lifevest |
| Cmp Pharma, INC. | $24.04 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.20 | 2024 | |
| Allergan, INC. | $18.72 | 2019 | |
| Philips North America LLC | $14.20 | 2021 | |
| Merz North America, INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hermes Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.